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SUMMARY 
The prevalence of chronic kidney disease (CKD) is linked to the epidemics of obesity, 
diabetes and prediabetes. Abnormally elevated glomerular filtration rate (GFR), also called 
hyperfiltration, is common in diabetes and has been found to increase the risk of diabetes-
related CKD. Hyperfiltration has also been proposed as an initial step in the development of 
other types of CKD. However, the causes of hyperfiltration in persons without diabetes have 
not been definitively determined. Specifically, it is not known whether prediabetes, insulin 
resistance and physical inactivity are associated with hyperfiltration. In studies of 
hyperfiltration, GFR must be measured with sufficient accuracy, which is time-consuming 
and costly. Previous studies of hyperfiltration in the general population are few and limited 
by the use of estimated GFR, which is imprecise in the upper range of GFRs.  
 
As part of the Tromsø 6 study (2007 / 2008), we measured GFR in 1627 middle-aged people 
from the general population using an exact method. Subjects with diabetes, cardiovascular 
disease or known kidney disease were excluded. We found that impaired fasting glucose, but 
not fasting insulin levels, were associated with hyperfiltration. Leisure-time high-intensity 
physical exercise was associated with a reduced risk of hyperfiltration in men. In both 
genders, high-intensity exercise eliminated the positive association between fasting glucose 
and GFR. The sensitivity and specificity of estimated GFR for defining hyperfiltration was 
poor when validated against measured GFR. Longitudinal studies using measured GFR are 
needed to investigate whether hyperfiltration is a risk factor for CKD in the general 
population.  
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1. INTRODUCTION  
Chronic kidney disease (CKD) is a growing public health problem worldwide. 
Approximately 10% of the population in most Western and Asian countries has CKD [1;2], a 
condition that increases the risk of end-stage renal disease, cardiovascular disease and death 
[3]. The prevalence of CKD is linked to the epidemics of obesity, prediabetes and diabetes 
[4;5], but the causes of early stage CKD and its underlying pathological mechanism are 
unclear. Furthermore, little is known about how to prevent CKD at the population level. 
To gain knowledge about preventing CKD, it is important to investigate modifiable risk 
factors for the early stage of CKD. At this stage, renal function, assessed with the glomerular 
filtration rate (GFR), is normal or even above the normal range. Abnormally elevated GFR, 
also called hyperfiltration, is thought to be a pathological state that may eventually lead to 
renal damage. However, hyperfiltration is difficult to investigate with the widely used 
creatinine-based estimates of GFR (eGFRcre) because these estimates are imprecise and 
biased, particularly in the normal or upper range. Thus, the causes of hyperfiltration in the 
general population are largely unknown. 
The present study was designed to investigate the relationship between metabolic and 
cardiovascular risk factors and GFR, measured as iohexol clearance, in a representative 
sample of the general population. Using a cross-sectional design, this thesis investigates the 
associations between renal hyperfiltration, fasting glucose, insulin resistance and physical 
exercise in nondiabetic middle-aged people.  In addition, this thesis explores the limitations 
of using estimated GFR in studies of cardiovascular risk factors and GFR in the normal or 
upper range. 
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2. BACKGROUND 
2.1 Kidney function and the glomerular filtration rate 
The kidney serves several functions, including the excretion of waste products and the 
regulation of blood pressure, certain hormones and the electrolyte concentration in body 
fluids. These functions are conducted in the nephrons through filtration, reabsorption and 
secretion. The total number of nephrons varies among individuals and ranges from 500.000 
to 1.5 million in individuals with two kidneys [6]. The filtration process takes place in the 
glomerulus of each nephron. The rate of filtration, or the glomerular filtration rate (GFR), is 
the volume of fluid filtered from the renal glomerular capillaries into Bowman’s capsule per 
unit time (ml/min). The GFR is determined by the hydrostatic and oncotic pressure gradients 
between the capillaries and Bowman’s capsule (net ultrafiltration pressure), the surface area 
available for filtration and the hydraulic conductivity of the glomerular membranes. 
 
The whole-kidney GFR, usually referred to as GFR, is the product of the average filtration 
rate of each nephron (the single-nephron GFR) and the number of nephrons in both kidneys. 
The GFR varies considerably among individuals and with age, sex and body size [7;8]. The 
normal range of GFR according to age and gender is shown in Figure 1 [7]. To compare the 
GFRs of individuals with different body sizes, GFR is conventionally adjusted for the body 
surface area (BSA) and expressed as ml/min/1.73 m
2
. However, GFR can also be expressed 
without adjustment for BSA as absolute GFR (ml/min).  
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Figure 1. Normal GFR values in men and women, assessed by inulin clearance (adapted 
from Wesson [7], reprinted in NEJM 354;23. 2006 [8]). 
2.1.1 GFR measurement with exogenous filtration markers 
GFR can be measured by injecting an exogenous filtration marker into the patient and 
conducting timed blood or urine measurements of the marker. An ideal filtration marker is 
freely filtered across the basal membrane of the glomeruli and not secreted, metabolized or 
reabsorbed in the renal tubules or in any other organ. The plasma or urinary clearance of an 
ideal filtration marker equals the true GFR. 
The urinary clearance of inulin is considered the gold standard method of measuring GFR, 
but it is time-consuming, expensive and complicated [9]. Instead, the plasma- or urinary 
clearance of alternative filtration markers, including radio-contrast or isotope media such as 
iohexol, iothalamate and 
51
Chrom-EDTA, has been widely used. Urinary clearance is 
cumbersome and prone to measurement error in the urine samples. Plasma clearance is easier 
to perform and more precise than urinary clearance, given no extrarenal elimination [9]. 
Plasma clearance can be measured by assessing the plasma concentration of the marker in 
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several blood samples or in one blood sample (the single-sample method).  The single-
sample method, in which GFR is calculated using Jacobsson’s formula, has been found to 
correlate very well with the multiple-sample method [10;11] Multiple- and single-sample 
iohexol clearance also correlate well with inulin or 
51
Chrom-EDTA clearance (correlation 
coefficients ranging from 0.91 to 0.99) in different studies [9].  
2.1.2 Estimation of GFR by endogenous filtration markers. 
GFR measurement is still costly and inconvenient in most clinical settings and in 
epidemiological studies. Therefore, endogenous markers, such as creatinine or cystatin C, are 
used to estimate GFR. Creatinine, the most commonly used filtration marker, is a breakdown 
product of creatine phosphate. Creatinine is freely filtered in the glomeruli, but a small 
amount is also secreted by the tubules. The generation of creatinine is determined primarily 
by muscle mass but also by diet. Accordingly, the plasma creatinine level is proportional to 
muscle mass and varies with age, gender, race and body size. These non-GFR related 
determinants of creatinine have led to the development of creatinine-based formulas that 
incorporate age, sex, race and body size to improve GFR estimation. The widely used 
Modification of Diet in Renal Disease (MDRD) equation was developed on the basis of 
populations with CKD and has been shown to perform well when GFR < 60 ml/min/1.73 m
2
. 
The equation has lower precision and a larger bias when GFR > 60 ml/min/1.73 m
2
, and it 
has been shown to underestimate GFR at higher levels [12]. In 2009, another creatinine-
based equation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation, was developed in a combined population of CKD patients and healthy individuals. 
This equation has been found to perform somewhat better than the MDRD in the normal 
range [13]. However, all creatinine-based equations are prone to bias in individuals with 
reduced muscle mass or atypical body compositions.  
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Recently, cystatin C has emerged as a promising filtration marker. Cystatin C is a small 
protein produced by all human cells and is freely filtered, completely reabsorbed and 
catabolized by the proximal tubular cells. Several cystatin C-based equations (eGFRcys) 
have been developed. However, the performance of eGFRcys has not been established. 
Cystatin C levels do not depend on muscle mass; rather, they are affected by other non-GFR 
factors, such as obesity and inflammation [14;15]. Another problem with eGFRcys is the 
lack of a standardized method for measuring cystatin C [16].   
2.2 Chronic kidney disease  
2.2.1 Definition, prevalence and health burden of CKD 
Chronic kidney disease (CKD) is a condition characterized by a GFR below 60 ml/min/1.73 
m
2
 and/or signs of kidney damage (e.g., albuminuria) lasting for at least three months [17]. 
CKD is classified into 5 stages according to severity of the disease, in which stage 5 is 
regarded as renal failure (Table 1).  
Table 1. 
Stages of chronic kidney disease according to KDOQI-guidelines
Stage Description GFR (ml/min/1.73m²)
1 Kidney damage with normal or ↑ GFR ≥90
2 Kidney damage with mild ↓ GFR 60-89
3 Moderate ↓ GFR 30-59
4 Severe ↓ GFR 15-29
5 Kidney failure <15 (or dialysis)
GFR= glomerular filtration rate  
 
Only a small fraction of patients with CKD progress to end stage renal disease (ESRD). 
However, the prevalence of ESRD is increasing rapidly worldwide, and this condition is 
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associated with reduced quality of life, a very high mortality rate and high healthcare costs 
[18]. Moreover, CKD Stage 1 through 4, which affect approximately 10 % of the population, 
also increase the risk of cardiovascular disease, especially when GFR < 45 ml/min/1.73 m
2
 
and/or microalbuminuria (MA) is present [3].  
The CKD staging system has been criticized.  First, it does not account for the diversity in 
the etiologies, course and treatment of CKD. Second, the standard and widespread tool for 
staging CKD, GFR estimation with creatinine (eGFRcre), is imprecise and biased, 
particularly at levels above 60 ml/min/1.73 m
2
. Accordingly, it is difficult to differentiate 
between CKD Stages 1 and 2.  Third, the CKD staging system is based on the GFR level and 
does not take into account the patients’ age and gender.  This is problematic because the 
GFR declines with age and has been found to be lower in women than in men [19] (figure 1). 
Therefore, the level of GFR corresponding to CKD Stage 3 overlaps with the normal age- 
and gender-adjusted GFR values [20]. Thus, a substantial fraction of healthy older 
individuals, particularly in women, are diagnosed as having CKD Stage 3 without any 
significant disease [20]. Finally, having eGFRcre in the upper range (e.g., eGFRcre > 105 
ml/min/1.73 m
2
) has been associated with a higher mortality compared to having an eGFRcre 
of 60 to 90 ml/min/1.73 m
2 
[3]. These issues complicate the estimation of real risk and thus 
the implementation of prophylactic strategies. 
2.2.2 Lifestyle-related risk factors for CKD 
Diabetes, obesity, smoking and hypertension are considered important risk factors for CKD 
[4;21-24]. The prevalence of type II diabetes is increasing, and diabetes nephropathy, 
characterized by persistent albuminuria and a relentless decline in renal function, has become 
a worldwide epidemic. Recent evidence also indicates that the kidney damage process begins 
in prediabetes, which is defined as impaired fasting glucose or glucose intolerance [5]. 
Increased fasting glucose and HbA1c within the nondiabetic range have been associated with 
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the progression of urinary albumin excretion [25;26]. However, the independent role of 
prediabetes as a risk factor for CKD needs to be investigated further [27]. 
Overweight and obesity increase the risk of CKD and ESRD [4;22;28;29], and some studies 
have found a particularly detrimental effect of abdominal obesity [30;31]. Additionally, 
insulin resistance, which is related to abdominal obesity [32], has been found to increase the 
risk of CKD [33;34]. Physical exercise, on the contrary, has been associated with a reduced 
progression of urinary albumin excretion and a reduced risk of kidney function decline in 
both diabetics and nondiabetics [26;35-37].  Furthermore, the risk of ESRD or CKD-related 
death is reduced in physically active nondiabetic individuals, independent of body mass 
index and blood pressure [24].  
Why obesity, insulin resistance, smoking and prediabetes lead to renal damage and why 
physical exercise may be protective is not known.  Advanced glycation end products, 
adipokines, low-grade inflammation, oxidative stress and direct hemodynamic effects on the 
renal vasculature could be of importance [38-40]  
2.3 Hyperfiltration 
2.3.1 The hypothesis of glomerular hyperfiltration as a mechanism in CKD 
development  
Almost 90 years ago, Arataki reported that surgically removing one kidney (unilateral 
nephrectomy) in a rat led to the enlargement of the remaining kidney [41]. Later, it was 
found that the reduction of three-fourths or more of the renal mass leads to increased GFR, 
glomerular enlargement and subsequent injury to the remaining glomeruli [42-44]. Two to 
four weeks after unilateral nephrectomy in rats, single-nephron GFR increased by 
approximately 40%, mainly as a result of elevated plasma flow and capillary pressure in the 
remnant glomeruli because of renal arteriolar vasodilatation [45]. In 1981, Brenner and 
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Hostetter reported that glomerular pathological findings, such as foot process fusion and 
mesangial expansion, developed in rats with hyperfiltration [44].  They proposed the 
hyperfiltration theory and hypothesized that glomerular hyperfiltration and/or the 
concomitant increased glomerular pressure were in fact maladaptive and represented “a 
common pathway for renal injury” that eventually leads to glomerulosclerosis in a variety of 
conditions in which renal mass was reduced to below a critical level [43].  
Evidence presented by Brenner and others has also indicated that reducing hyperfiltration 
and/or glomerular pressure with a low-protein diet or the use of renin-angiotensin system 
inhibitors protects against renal injury in animals and in humans with diabetes or reduced 
functional renal mass [43;46;47]. However, later studies have revealed that glomerular 
hyperfiltration can exist without a concomitant increase in glomerular capillary pressure, 
possibly because of the close relationship between hyperfiltration and glomerular growth 
[48]. Increased glomerular capillary surface area can increase single-nephron GFR with 
constant glomerular capillary pressure. Furthermore, evidence suggests that increased 
glomerular pressure, rather than hyperfiltration per se, is the most critical determinant of 
glomerular injury [48]. Nevertheless, experimental studies strongly suggest that glomerular 
growth and/or its functional counterpart, glomerular hyperfiltration, cause podocyte stress 
and damage that may lead to glomerulosclerosis [49]. Whether glomerular hyperfiltration 
causes glomerular growth or vice versa has not been settled [50].  Renal enlargement was 
found to precede hyperfiltration in a study of diabetes in rats [51].   
 
Diabetes and obesity are associated with an early phase of abnormally elevated whole-kidney 
GFR, which often precedes CKD in these conditions [40;52]. A marked elevation in whole-
kidney GFR within the same subject has been considered to be closely correlated with 
hyperfiltration at the single nephron level. Accordingly, it has been postulated that prolonged 
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whole-kidney hyperfiltration may lead to albuminuria, irreversible structural glomerular 
changes, glomerulosclerosis and, ultimately, to reduced GFR and CKD [53] (Figure 2).  
 
 
Figure 2. Time course of GFR and albuminuria/proteinuria in a hypothetical subject 
(adapted from Ruggenenti P., Kidney International 2006). 
2.3.2 Renal hyperfiltration in humans 
To date, there are no methods for determining single-nephron GFR in humans. However, in 
situations where a small intraindividual or interindividual variation in the number of 
nephrons can be assumed, changes in the total GFR can be assumed to reflect changes in the 
mean single-nephron GFR. Thus, investigators use whole-kidney hyperfiltration, hereafter 
referred to as renal hyperfiltration, as a proxy for glomerular hyperfiltration. However, there 
is no consensus on how to define renal hyperfiltration.  In diabetes, renal hyperfiltration is 
often defined as having a GFR greater than the mean GFR + 1.96 x the standard deviation of 
nondiabetic control subjects [54]. A threshold has also been arbitrarily set at 125 to 140 
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ml/min/1.73 m
2
 in some studies [55;56]. In studies of individuals without diabetes, the 
threshold has varied from having a GFR in the upper quintile of the total study group to 
having a GFR above the age- and sex-specific 95
th
 or 97.5
th
 percentile of healthy participants 
[57-59]. 
2.3.3 Experimental studies of disturbed glucose metabolism and renal hyperfiltration 
In patients with diabetes and in healthy humans, increased GFR has been induced by acute 
glucose infusion and has resulted in plasma glucose levels between 7.2 and 16.0 mmol/l in 
different studies [60-62]. However, Mogens et al. found no GFR increase in healthy men 
after oral glucose intake when plasma glucose levels were raised from 4.4 to 7.6 mmol/l [62]. 
Whether chronic hyperglycemia in the nondiabetic range (fasting glucose: 5.6 to 6.9 mmol/l) 
independently influences GFR in humans has not been investigated.  In dogs, however, a 
continuous glucose infusion for 6 days that produced a modest rise in serum glucose (from 
6.5 to 7.1 mmol/l) increased GFR significantly [63].  
While evidence suggests that glucose per se elevates GFR in type I diabetes, the concomitant 
rise in insulin levels (in response to hyperglycemia) may play a role in type II diabetes and/or 
in healthy subjects. Treatment with rosiglitazone, an insulin sensitizing drug, has been shown 
to blunt hyperfiltration in type II diabetes without a significant change in glucose levels [64]. 
In isolated, perfused rat kidneys, insulin infusion at physiological levels caused renal 
vasodilatation and increased the glomerular filtration rate, most likely via a prostaglandin-
dependent process [65]. However, not all experimental studies have found that 
hyperinsulinemia causes an increase in GFR [40]. In rat micropuncture studies, insulin 
infusion during euglycemic clamping increased the mean single-nephron GFR in normal rats 
but reduced the GFR in diabetic rats [66].  
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2.3.4 Diabetes and renal hyperfiltration 
Early type I diabetes is associated with enlarged kidneys and renal hyperfiltration, which are 
caused by hyperglycemia [67;69]. Moreover, intensive insulin treatment in type I diabetes 
has been shown to reverse hyperfiltration [68] and decrease kidney size [69;70]. Similarly, at 
the early stage of type II diabetes, some 40% of patients have an eGFR more than two 
standard deviations above the mean for the general population [50]. Renal hyperfiltration in 
type I and II diabetes tends to precede microalbuminuria, whereas the GFR may decline as 
proteinuria develops [52;71]. A recent meta-analysis of studies that measured GFR in people 
with type I diabetes found an increased risk of progression from normoalbuminuria to 
microalbuminuria or overt albuminuria in subjects who had renal hyperfiltration at baseline 
(OR 2,7 [CI: 1.2-6.1]) [55]. Also, the progression from hyperfiltration to reduced GFR has 
been shown without an increase in urinary albumin excretion [72]. However, whether 
hyperfiltration is a cause of diabetic nephropathy is still debated, often with reference to the 
cystatin C-based 1
st
 Joslin Kidney Study on the natural history of microalbuminuria in type I 
diabetes [50;73]. In that study, in which 426 normoalbuminuric type I diabetes patients were 
followed for 15 years, the risk of developing microalbuminuria was not increased in 
individuals with hyperfiltration, as determined by cystatin C levels. 
  
2.3.5 Obesity and renal hyperfiltration 
Several studies show higher absolute GFR measurements in obese individuals compared to 
their lean counterparts [40;56]. Some of these studies demonstrate a significant reduction in 
GFR after weight loss [40]. It has been postulated that higher metabolic demands resulting 
from increased body weight lead to elevated GFR [48]. The underlying mechanisms and the 
signals that communicate these metabolic needs to the kidney are unknown.  
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The elevated absolute GFR in obesity is obscured by the current practice of indexing GFR to 
body surface area (BSA). This issue was recently illustrated in a study of 301 individuals 
without diabetes in which GFR was measured with inulin. In this study, overweight 
(BMI>25) and obesity (BMI>30) were associated with hyperfiltration when it was defined as 
GFR > 140 ml/min but not when hyperfiltration was defined as GFR > 140 ml/min/1.73 m
2
 
[56]. Because the nephron number does not increase in individuals who gain weight, 
increased absolute GFR is generally considered to also represent increased GFR at the single 
nephron level.  
Interestingly, both diabetes and obesity are associated with renal hyperfiltration and 
glomerular enlargement/growth in an early phase. At a later stage, obesity-related 
glomerulopathy and diabetic nephropathy share several renal histological findings, including 
segmental glomerulosclerosis, glomerular basement membrane thickening and foot process 
fusion [74].  
2.3.5 Prediabetes, insulin resistance and renal hyperfiltration  
Few clinical studies have investigated the association between prediabetes or insulin 
resistance and renal hyperfiltration. Impaired glucose tolerance was associated with elevated 
GFR in a study of Pima Indians [75], but these findings lost significance when GFR was 
adjusted for body size. In a study of never-treated hypertensive patients, fasting glucose was 
associated with higher mGFR, but the authors did not specify whether GFR was adjusted for 
body surface area (in the multivariable adjusted analysis), and the association between 
glucose and hyperfiltration (yes/no) was not investigated [76]. In another study of Stage 1 
hypertensive subjects in which GFR was assessed via urinary creatinine clearance, plasma 
glucose was not associated with hyperfiltration [57]. Neither of these studies provided 
information about insulin levels. Hyperinsulinemia has been shown to correlate with 
increased GFR and filtration fraction in overweight individuals with mild hypertension in a 
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study using the hyperinsulinemic euglycemic clamp technique [77].  However, as reviewed 
by Griffin et al., it is not likely that hyperinsulinemia is a major or direct cause of 
hyperfiltration in obesity. Alternative mechanisms, such as increased proximal sodium 
reabsorption through increased sympathetic activity or the activation of the renin-angiotensin 
system, could be of importance [78]  
2.3.6 Physical exercise and renal hyperfiltration 
Exercise conveys general protective effects on vascular function in humans and has been 
associated with the regression of urinary albumin excretion in both diabetics and non-
diabetics [26;79;80]. Nevertheless, no experimental or epidemiological studies have 
addressed the effect of exercise on hyperfiltration. However, exercise training has been 
shown to influence brachial arterial flow-mediated dilation and to lower resting renal nerve 
activity in healthy men, factors that could influence GFR [81;82]. Furthermore, exercise 
reduces oxidative stress and inflammation, which have been associated with hyperfiltration 
in several experimental studies [83;84].  
2.3.7 Epidemiological studies of renal hyperfiltration. 
Few population-based studies have addressed the issue of hyperfiltration in nondiabetic 
individuals. In a study of 1572 young healthy men (mean age: 18 years), hyperfiltration was 
associated with body mass index (BMI), blood pressure and low HDL cholesterol but not 
with fasting glucose or insulin levels [85]. However, in this study, the creatinine-based 
Cockroft-Gault formula was used to estimate GFR, and it is known to overestimate GFR in 
obese individuals [86]. A limitation of all studies that estimate GFR is the possible bias and 
poor precision in the normal and upper ranges of eGFR [9]. Bias is of particular concern in 
studies of metabolic risk factors and creatinine-based eGFR because these risk factors 
correlate with body composition and muscle mass and therefore with creatinine production. 
 21 
Whether eGFRcys performs better than eGFRcre in studies of cardiovascular or metabolic 
risk factors and GFR in the upper range needs to be determined.  
In the Prevention of Renal and Vascular End-stage Disease study (PREVEND), a population-
based study using 24-h creatinine clearance (Ccr), microalbuminuria [58] and smoking [87] 
were associated with renal hyperfiltration. Although the latter study did not comment on it, 
glucose was also associated with renal hyperfiltration (defined as the mean Ccr + 1.96 
standard deviation). However, in that study, the laboratory definition of diabetes was fasting 
glucose ≥ 7.8 mmol/l, which is above the current cut-off limit for diabetes (≥ 7.0 mmol/l).   
In another PREVEND publication, higher insulin levels were associated with a higher age-
specific Ccr in younger individuals but a normal or reduced age-specific Ccr in older 
individuals [88]. The authors interpreted this finding as a tendency for hyperfiltration at 
younger ages leading to accelerated renal function loss later in life [88]. However, although 
urinary Ccr is not influenced by body composition and/or creatinine production, its accuracy 
is far from optimal and perhaps not better than that of eGFR [9].  
Accordingly, the causes of hyperfiltration in the general population are not settled. In 
particular, it is not known whether prediabetes, hyperinsulinemia, insulin resistance or 
physical inactivity are associated with hyperfiltration.  
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2. AIMS OF THE STUDY 
Primary aim: 
• To investigate whether renal hyperfiltration is associated with glucose metabolism or 
physical exercise in the nondiabetic general population. 
Secondary aim: 
• To explore the validity of using GFR estimated from creatinine or cystatin C in 
epidemiological studies of cardiovascular and chronic kidney disease in the 
nondiabetic general population.    
 
3. METHODS 
3.1 Subjects 
The Renal Iohexol-Clearance Survey in Tromsø 6 (RENIS-T6) is a part of the sixth Tromsø 
study. The Tromsø study is a population-based survey of inhabitants in the municipality of 
Tromsø, in northern Norway (current population: 65 000). The primary focus of the Tromsø 
study has been to explore the prevalence of and risk factors for cardiovascular disease. 
Tromsø 6 was conducted between October 2007 and December 2008. A random and age-
stratified sample of 19 762 persons were invited. Among the people invited to participate 
were 40 % of all inhabitants between the ages of 50 and 59 years and all inhabitants between 
60 and 62 years. A total of 12,984 persons were examined, giving an overall attendance rate 
of 66%. 
RENIS-T6 was conducted between November 2007 and June 2009, and invited participants 
of Tromsø 6 at the age of 50 - 62 years. The 50 - 62-year-old age group was chosen in order 
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to provide a relatively healthy population with a high attendance rate and a sufficient risk of 
CKD and cardiovascular disease for a later end-point study.  In the age groups of interest, 
3564 of 5464 (65%) completed the main part of Tromsø 6, which included a physical 
examination and a self-administered questionnaire. From this group, we excluded 739 
participants who reported previous myocardial infarction, angina pectoris, stroke, diabetes 
mellitus, or renal disease (Figure 2). The remaining 2825 people were invited to participate 
in RENIS-T6, and 2107 (75%) responded positively. Twelve people were excluded because 
of allergies to contrast media, iodine, or latex; 65 were excluded for other reasons (e.g., 
recent CVD); and 48 did not appear for their appointments. From the remaining 1982 
persons, we consecutively included 1632 individuals according to a predetermined target size 
and stratified by sex and age group. The target sample size was based on the expected effect 
of GFR on the primary cardiovascular end point of the longitudinal portion of RENIS-T6.  
Five participants were excluded because their iohexol clearance measurements were 
technical failures, leaving 1627 persons in the RENIS-T6 cohort. 
 
In paper 1 (n=1560), we excluded 33 participants who had diabetes according to their fasting 
plasma glucose (≥7.0 mmol/l) or HbA1c level (≥ 6.5%) and 34 with CKD, defined as a 
measured GFR < 60 ml/min/1.73 m
2
. 
In paper 2 (n=1506), we excluded another 54 participants who had missed information on the 
main exercise questions. 
In paper 3, the study population (n=1627) consisted of the total RENIS-T6 cohort. 
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Figure 2. Flowchart of the RENIS-T6 study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Data collection and measurements 
Study participants met in the morning at the Clinical Research Unit at the University 
Hospital of Northern Norway after an overnight fast. The participants had been instructed to 
N = 5464 
Invited to the Tromsø 6 Study 
and aged 50 to 62 years
N = 3564 (65%)
Met and completed the 
main Tromsø 6 Study N = 739
Reported a previous myocardial 
infarction, angina pectoris, stroke, 
diabetes mellitus, or any renal disease 
except urinary tract infection. 
N = 2825
Invited to RENIS-T6
N = 2107 (74%)
Responded
N = 1632
Investigated in RENIS-T6 according 
to a predetermined target
N = 1627
The RENIS-T6 cohort
N = 1506
Present study population
N = 125
Excluded because of allergy to contrast
media, iodine, or latex, or for other reasons. 
Includes 48 who withdrew.
N = 5
Technical failure in the 
iohexol-clearance measurements. 
N = 121
Diabetes (N = 33) according to their fasting 
plasma glucose or HbA1c, CKD (N = 34) 
defined as measured GFR< 60 ml/min/1.73 m2, 
or missing information on exercise (N = 54)
N = 1982
Eligible for inclusion
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refrain from tobacco smoking for the previous 12 hours and to drink two glasses of water 
before arrival. After arrival, the participants completed a questionnaire about their current 
medications. Body weight and height were measured. A Teflon catheter was placed in an 
antecubital vein, and fasting plasma samples were drawn for biochemical analyses.  
3.2.1 Clinical variables and assessment of physical exercise  
As part of Tromsø 6, all participants had completed a self-administered questionnaire 
regarding smoking status, physical exercise, and health status, including current or previous 
diabetes, cardiovascular disease or renal disease (appendix 1). We used three questions 
addressing the frequency, intensity, and duration of leisure-time physical exercise to assess 
the level of physical exercise (table 1, paper 2, and appendix 1). The information from the 
question on general physical activity (during leisure) or during working hours was not used 
in this study.  
3.2.2 Ambulatory and conventional blood pressure measurements  
Conventional blood pressure was measured 3 times at 2 minute intervals using an automatic 
device (A&D Model UA-799; Tokyo, Japan) after two minutes of rest in a seated position. 
The average of the last two readings was used. Ambulatory blood pressure was measured 
after the iohexol clearance measurement and through the next day. An appropriate cuff size 
was used. More details on the ambulatory blood pressure measurement can be found in the 
Methods section of paper 2.  
3.2.3 Measurement of iohexol clearance  
The plasma clearance of iohexol was measured using a single-sample method. Five 
milliliters of iohexol (Omnipaque, 300 mgI/mL, Amersham Health, London, U.K.) were 
injected through the venous catheter, and the syringe was weighed before and after injection. 
The venous catheter was flushed with 30 mL of isotonic saline. The participants were then 
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allowed to have a light breakfast and to walk around until the iohexol blood sample was 
drawn from the same catheter. The optimal time for measuring iohexol concentration after 
injection was calculated using Jacobsson`s method, and based on the GFR estimated from 
creatinine [89]. The exact time between the iohexol injection and sampling for each person 
was measured in minutes, using a stopwatch. The serum iohexol concentration was measured 
using high-performance liquid chromatography, as described by Nilsson-Ehle [90]. The 
iohexol concentration was calculated using the area under the largest iohexol peak and 
comparing it with suitable external standards of iohexol. The analytical coefficient of 
variation during the study period was 3.0%.  
The GFR was calculated using the formula described by Jacobsson, in which a small 
correction is made for nonimmediate mixing and for nonuniform distribution of the tracer 
[89]. Extracellular volume (distribution volume) was estimated using Granerus` equation 
[91]. The extrarenal iohexol clearance was ignored, in accordance with previous studies. 
Further details about the iohexol clearance measurement in RENIS-T6 have been published 
elsewhere [92].   
3.2.4 Biochemical analyses 
Creatinine analyses were performed with an enzymatic method that was standardized against 
isotope dilution mass spectroscopy (CREA Plus, Roche Diagnostics, GmbH, Mannheim, 
Germany). Cystatin C was measured using a particle-enhanced turbidimetric immunoassay 
method (Gentian, Moss, Norway). The serum glucose, triglycerides, total cholesterol, LDL 
cholesterol, and HDL cholesterol concentrations were measured on a Modular P800 (Roche 
Diagnostics) the same day. 
Samples for insulin measurement were immediately frozen at  –80˚C.  Later, the samples 
were thawed once, and insulin was measured with an ELISA kit (DRG Instruments, 
Marburg, Germany). The intra- and interassay coefficients of variation were 4.7 % and 6.3 
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%, respectively. HbA1c was measured with a liquid chromatographic method in the main part 
of Tromsø 6. 
Urinary albumin excretion and urinary creatinine were measured in the main part of Tromsø 
6. Three samples of first-void morning spot urine were collected on separate days. The urine 
samples were tested with a dipstick and analyzed unfrozen on the same day for albumin and 
creatinine using commercial kits, as described in a previous study [26]. Albuminuria was 
reported as the albumin/creatinine ratio (ACR, mg/mmol). Urine creatinine was measured 
using colorimetric methods (Jaffe’s reaction) with an autoanalyzer (ABX PENTRA, Horiba 
ABX, Montpellier, France). The urine albumin concentration was measured using the  
immunoturbidimetric method and an ABX PENTRA autoanalyzer (Horiba ABX, 
Montpellier, France). For each subject, the ACR was determined for each of the 3 separate 
urine samples, and the mean of all 3 was used in the analyses. 
3.2.5 Definition of hyperfiltration and other variables 
 Renal hyperfiltration was defined as an absolute mGFR (in mL/min) above the 90
th
 
percentile after adjusting for gender, age, weight, height, and the use of angiotensin 
converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARB). Accordingly, 
hyperfiltrators were determined by selecting all subjects who were above the 90
th
 percentile 
in the distribution of residuals from a multiple linear regression analysis in which we used 
the logarithm of absolute GFR as a dependent variable and gender, ACE-i or ARB use, and 
the logarithms of age, weight, and height as independent variables. 
Impaired fasting glucose (IFG) was defined as a fasting plasma glucose between 5.6 and 6.9 
mmol/l according to the American Diabetes Association criteria. Insulin resistance was 
expressed by the homeostasis model assessment (HOMA-IR), which was calculated by 
multiplying fasting glucose (mmol/L) by fasting insulin (mU/L) and dividing the result by 
22.5 [93]. The participants were categorized as being current smokers or nonsmokers (former 
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smokers were included in the nonsmoker group). Physical exercise was categorized 
according to the frequency, intensity and duration of exercise (paper 2). In paper 3, physical 
activity was dichotomized into active (those who perform hard physical activity for > 1 hours 
per week (with sweating or breathlessness) and/or light physical activity for > 3 hours per 
week (without sweating or breathlessness)) or inactive (the remaining participants).   
To estimate GFR from creatinine, we used the recalibrated four-variable MDRD equation 
(eGFRMDRD) [94] and the CKD-EPI equation (eGFRCKD-EPI) [13] (table 1, paper 2). Among 
several existing cystatin C-based equations, we used Rule’s cystatin C-based equation of 
2006 (eGFRcys)[95] because this equation performed well compared with other cystatin C 
equations validated against measured GFR in the general population (RENIS-T6) [92].   
 
3.3 Statistical analyses 
The age- and sex-adjusted means, geometric means and median values of the population 
characteristics are presented according to fasting glucose group (paper 1) or physical exercise 
level (paper 2). In paper 3, we divided participants into gender- and method-specific quintiles 
for mGFR and eGFR. Differences across groups were tested by analysis of covariance 
(ANCOVA) or linear regression for mean values, quantile regression for median values and 
multiple logistic regression for dichotomous variables.  
The association between mGFR (in ml/min/1.73 m
2
) and fasting glucose, HbA1c, fasting 
insulin, HOMA-IR (paper 1) and cardiovascular risk factors (paper 3) were assessed by 
multiple linear regression analysis, adjusting for known or possible determinants of GFR (see 
paper 1 and 3 for details on adjustments). In paper 1, the same multiple linear regression 
models were repeated with GFR expressed in ml/min (i.e., absolute GFR, not indexed for 
body surface area). To reflect the multiplicative relationship between variables, we also 
repeated regression analyses when GFR, age, weight and height were transformed to natural 
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logarithms. Possible nonlinear relationships were explored with generalized additive models 
using smoothing with cubic splines [96].  
The associations between hyperfiltration (yes/no) and fasting glucose, HbA1c, fasting 
insulin, HOMA-IR and exercise categories were assessed with multiple logistic regression, 
adjusting for the same variables that were used in the linear regression analyses.  
We tested for interactions between age, gender and all of the other independent variables in 
both the linear and logistic regression analyses. We also tested for a possible interaction 
between fasting glucose, fasting insulin and physical exercise in their effect on mGFR and 
hyperfiltration (yes/no; described in detail in paper 2).  
In paper 2, we repeated all analyses when the absolute GFR in mL/min was adjusted to 40 
liters of total body water (GFR40, instead of indexing by 1.73 m
2 
of body surface area), as 
recently suggested in another RENIS-T6 publication [97]. In addition, we defined 
hyperfiltration as a GFR40 above the 90
th
 percentile after adjusting for age, ACE-I and ARB 
only.  
The sensitivity and specificity for detecting individuals with hyperfiltration (based on 
measured GFR) was calculated for the Rules cystatin C equation and the creatinine-based 
eGFRCKD-EPI equation. In these analyses, eGFRcys and eGFRCKD-EPI were used to define 
hyperfiltrators using the same method described for mGFR, by selecting individuals with 
eGFR (in ml/min/m
2
) > 90
th
 percentile adjusted for age, sex, weight, height, and the use of 
ACE-i or ARB. 
To study whether eGFR was associated with non-GFR related CVD risk factors, we 
performed a multiple linear regression with eGFR as the dependent variable, CVD risk 
factors as independent variables, and mGFR added as an adjusting variable. The analysis was 
repeated with errors-in-variables regression to account for the reduced reliability of mGFR 
[98].  
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4. MAIN RESULTS 
4.1 Paper 1. Impaired fasting glucose is associated with renal 
hyperfiltration in the general population 
A total of 311 (40%) males and 141 (18%) females had impaired fasting glucose (IFG). After 
adjusting for age and sex, individuals with IFG had higher BMIs, fasting insulin levels, and 
blood pressure but not higher albumin-creatinine ratio (ACR) compared with those with 
normal fasting glucose levels (P < 0.05). Measured GFR, but not creatinine- or cystatin C-
based estimates of GFR, was higher in those with IFG (P = 0.002). 
Fasting glucose, HbA1c, fasting insulin, and HOMA-IR were all positively associated with 
mGFR in separate multiple linear regression models adjusted for age, gender, weight, height, 
diastolic blood pressure, current smoking, and ACEi or ARB use (P<0.05) (table 3, paper 1) 
The effect estimates of insulin and HOMAR-IR were not significant when fasting glucose 
was included in the models. A multivariable-adjusted, non-linear association between fasting 
glucose and mGFR was observed in a generalized additive model. GFR increased with 
higher glucose levels, with a steeper slope beginning at fasting glucose > 5.6 mmol/L (figure 
1, paper 1). 
The mean GFRs for female (n = 79) and male (n = 77) hyperfiltrators were 110.1 (range: 
98.7 – 138.6) and 118.2 (range: 107.5 – 137.3) ml/min/1.73 m
2
, respectively.  
The multivariable-adjusted odds ratio of hyperfiltration per one unit increase in fasting 
glucose, HbA1c and HOMA-IR and for having IFG were 1.97 (95% CI, 1.36 - 2.85), 2.23 
(95% CI, 1.30 - 3.86), 1.14 (95% CI, 1.01 - 1.28) and 1,56 (1.07 – 2.25), respectively. 
Fasting insulin level was not associated with hyperfiltration, and the significance of HOMA-
IR disappeared when fasting glucose was included in the model.  
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4.2 Paper 2: Renal hyperfiltration – Sex-specific effects of high-
intensity exercise and fasting glucose 
Eight hundred seventy-seven (58.3%) of the participants exercised at least two times a week 
(table 2, paper 2). The frequency and intensity of exercise were correlated (r = 0.30, P < 
0.001). After adjusting for age and sex, more intensive exercise was associated with a lower 
percentage of smoking (P < 0.001), lower HDL cholesterol (P < 0.05), lower ambulatory 
heart rate (P < 0.001), and lower eGFRcre (P < 0.05). Measured GFR or eGFRcys, however, 
did not differ between exercise levels. 
High-intensity exercise reduced the adjusted odds ratio of hyperfiltration in men (0.5; P < 
0.01) but not in women. The effect of exercise intensity on hyperfiltration in men remained 
similar and significant after adjustment for exercise frequency and duration (data not shown). 
Exercise frequency tended to reduce the odds of hyperfiltration in women, but the linear 
trend was not statistically significant (P = 0.2). 
In the multiple linear regression analysis, high-intensity exercise eliminated the positive 
association between fasting glucose and GFR in both sexes. A one-unit increase in glucose 
was associated with 7.3 and 6.2 ml/min/1.73 m
2
 higher GFR in men and women, respectively 
(P < 0.001), but only in individuals who never exercised or exercised with low intensity 
(interaction, P < 0.001). Similar but attenuated results were found for eGFRcys but not for 
eGFRcre (shown for eGFRCKD-EPI, table 5, paper 2). 
The same pattern of effect modification by exercise was found for the association between 
glucose and hyperfiltration (table 6, paper 2).  However, the interaction between exercise 
category and glucose on hyperfiltration did not reach statistical significance when all of the 
subjects were analyzed using the same model (P = 0.25). Exercise did not modify the 
association between insulin resistance and GFR or hyperfiltration (not shown), but it tended 
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to modify the association between HbA1c and GFR/hyperfiltration in a way similar to that 
found for fasting glucose (not significant). 
 We obtained essentially the same results when GFR was normalized by total body water 
(GFR40) and when hyperfiltration was defined as GFR40 above the 90
th
 percentile and 
adjusted for age, ACE-I and ARB (not shown).  
4.3 Paper 3. Estimated GFR is associated with cardiovascular risk 
factors independently of GFR 
In the RENIS-T6 cohort (N=1627), the mean mGFR was 87.8 ml/min/m
2
 in women and 95.7 
ml/min/m
2
 in men. The mean eGFRcre, however, was slightly lower in women, and the mean 
eGFRcys was 2.2 ml/min/m
2
 higher in women than men (table 1, paper 3). In the 
multivariable-adjusted regression model, mGFR was positively associated with current 
smoking (β=2,87, P < 0.001) and negatively associated with diastolic blood pressure (β = -
0.94, P < 0.05; per standard deviation increase).  BMI and HDL cholesterol were associated 
with higher mGFR in men but not in women (P for gender interaction < 0.05). 
 
Several CVD risk factors influenced eGFR after adjusting for mGFR (table 4, paper 3). 
Current smoking was associated with a 3.9 ml/min/1.73 m
2
 higher GFRMDRD, a 1.6 
ml/min/1.73 m
2
 higher GFRCKD-EPI and a -8.9 ml/min/1.73 m
2
 lower eGFRcys after adjusting 
for all of the independent variables and mGFR (P < 0.001). More risk factors influenced 
eGFRcys than eGFRcre after adjusting for mGFR. Smoking, BMI, triglycerides and HDL 
cholesterol were associated with eGFRcys in the fully adjusted model (P < 0.001). The 
results from errors-in-measurements regression were similar. Analyses with generalized 
additive models revealed nonlinear effects of BMI on eGFRcre and of triglycerides on 
eGFRcys after adjusting for mGFR (P < 0.05; shown in Figure 1, Paper 3). 
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In analyses of ten-year cardiovascular risk scores (estimated with the Framingham equation) 
across quintiles of mGFR and eGFR, lower eGFRcys was associated with a higher 
cardiovascular risk score in both sexes (P for trend <0.001). However, the cardiovascular risk 
score was not different across mGFR and eGFRcre quintiles for men, and it increased across 
mGFR and eGFRcre quintiles for women (P for trend < 0.05).  After adjustment for 
smoking, the difference in cardiovascular risk score was no longer significant across 
eGFRcre and mGFR quintiles in women, but it was still significant for eGFRcys in both 
sexes. 
4.4 Additional analysis  
In the logistic regression analyses performed in paper 1, we found that current smoking was 
independently associated with renal hyperfiltration (odds ratio: 2.12; P < 0.001; not 
presented in paper 1). 
The sensitivity and specificity for defining hyperfiltration with eGFRCKD-EPI were 0.36 (95% 
CI, 0.28 – 0.44) and 0.93 (CI, 0.91 – 0.94); for eGFRcys, they were 0.30 (CI, 0.23 – 0.38) 
and 0.92 (CI, 0.91 – 0.94). 
In agreement with the linear and logistic regression analyses that used mGFR as a dependent 
continuous or dichotomous variable (tables 2 and 3, paper 1), we found a similar but 
attenuated association between fasting glucose and eGFRcys (β= 2.75.ml/min/m2, P < 0.05) 
and between fasting glucose and hyperfiltration based on the eGFRcys (OR = 1.5, P < 0.05). 
There were no associations between fasting glucose and eGFRcre or hyperfiltration defined 
according to the eGFRcre. Current smoking was associated with an increased odds ratio of 
hyperfiltration defined by eGFRcre (for eGFRCKD-EPI; OR = 1.8, P < 0.05) but a decreased 
odds ratio of hyperfiltration defined by eGFRcys (OR = 0.35, P < 0.001). 
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5. GENERAL DISCUSSION 
5.1 Methodological discussion 
5.1.1 Design 
The RENIS-T6 was designed as a prospective cohort study. This thesis is based on cross-
sectional investigations of baseline data from the RENIS-T6. The information and data were 
recorded at a single point in time or within few months. Thus, as in other cross-sectional 
studies, no definite conclusions about cause and effect relationships can be drawn. 
5.1.2 Bias 
Bias is defined as the result of a systematic error in the design or conduct of the study [99]. A 
study with little bias is considered valid. Bias can be divided into two main categories: 
Selection bias and information bias [100]. 
5.1.2.1 Selection bias 
Selection bias occurs when there are “different probabilities of being included in the study 
sample according to the presence of the exposure or outcome of interest” [100]. In the 
current study, individuals were first invited to participate in the main Tromsø 6 study and 
thereafter to the RENIS-T6. The attendance rate for the main Tromsø 6 study was 66%, and 
the response rate in RENIS-T6 was 77%, which is high compared to similar studies in other 
countries. However, some selection bias may still be present. For example, having enough 
time or energy to participate in a study or being concerned about one’s own health could 
affect lifestyle-related risk factors (e.g., diet and exercise) and the probability of participating 
in a study. To assess the magnitude of selection bias, one should compare the characteristics 
of those who participate and those who were eligible to participate and did not. We do not 
have data on nonattendees of Tromsø 6, but we have information about the study 
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characteristics of all subjects who were eligible for RENIS-T6. There were only small 
differences between those included in the study (n = 1621) and all eligible persons (n = 2825) 
[92].  
Another possible bias in cross-sectional studies is healthy survival bias. Survival bias in our 
study could exist if, for example, smokers with high GFRs were oversampled because 
smokers with low GFRs had higher mortality and thus had died.  However, because we 
excluded all persons with known CKD, mGFR < 60 ml/min/1.73 m
2
, CVD or diabetes, this 
type of bias is less likely.  
Incident-prevalence bias may exist if the exposure of interest affects the duration of the 
outcome. In our study, this could be a problem when examining the risk of hyperfiltration. 
We found a small and borderline significant increased odds ratio of hyperfiltration by insulin 
resistance (assessed using the HOMA index). Let us assume that both fasting glucose and 
insulin resistance cause hyperfiltration to the same degree but that hyperfiltration in the 
presence of insulin resistance has a shorter duration before progressing to proteinuria and 
decreased GFR (e.g., because of concomitant hypertension or endothelial dysfunction). The 
point prevalence of hyperfiltration would therefore be higher during hyperglycemia than 
during insulin resistance. Similarly, there could also be other short-term risk factors for 
hyperfiltration that are difficult to assess in a cross-sectional study. 
5.1.2.2 Information Bias 
Information bias occurs if definitions of study variables are inadequate or if data collection is 
flawed. This may result in systematic errors and data that, on average, differ from the truth 
[99]. 
Some exposure variables in the current study were obtained with a questionnaire. Subjective 
interpretation of questions (e.g., in the reporting of smoking or physical exercise) is possible. 
Such errors could lead to misclassification, which also could differ between subgroups, e.g., 
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between men and women. This factor could explain the sex disparity in the effect of high-
intensity exercise that we found in our study. Nevertheless, it is unlikely that such 
misclassification is substantial because intensive exercise tends to be better reported than 
less-intensive exercise [101;102]. 
Another issue is the possibility that errors in the reporting of exercise could differ according 
to glycemic status or other health-related factors that also affect GFR. In this case, a 
differential misclassification may occur, which could have biased the estimates in either 
direction. However, the exercise questions in the current study were recently found to have 
good reproducibility and acceptable validity in studies that assessed physical fitness by 
measuring maximal oxygen consumption (VO2max) [103;104]. However, one of these studies 
included only men. Additionally, the questionnaire had higher validity for assessing more 
intense physical activity than overall energy expenditure [103]. This could explain why the 
effect of physical exercise in the current study was intensity dependent. On the other hand, 
several studies have found that the intensity of exercise is crucial for improving fitness and 
endothelial function and thus cardiovascular outcome [79;104;105].  
 
Information bias because of stress from participating in the study is also a possibility. Mental 
stress triggers the sympathetic nervous system, which again could influence the level of 
fasting insulin or fasting glucose [106]. Furthermore, stress causes vasoconstriction, and 
likely also causes vasoconstriction in the kidney, and could thereby affect GFR, which was 
measured over a short period of time [107]. Therefore, stress could bias the level of the risk 
factor and the dependent variable (hyperfiltration) and lead to differential misclassification. 
However, regarding the results in paper 2, exercise did not alter the renal vascular response 
to mental stress in a study of healthy humans [108]. 
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5.1.1.3 Temporal bias 
In cross sectional studies, no cause-and-effect relationship can be firmly established. 
Temporal bias occurs when inferences about a temporal sequence of cause and effect are 
made erroneously [100].  For example, the main hypothesis put forward in the current thesis 
is that elevated fasting glucose causes hyperfiltration. Instead, the opposite (that elevated 
GFR causes hyperglycemia) is also possible. However, although the kidneys play a role in 
endogenous glucose production [109], this direction of causality is less biological plausible. 
Furthermore, experimental evidence supports that an infusion of glucose in humans causes 
the GFR to rise [60;61].  
5.1.3 Definition of renal hyperfiltration 
There is no consensus on how to define hyperfiltration. In line with previous studies, we 
chose an arbitrary level of GFR as a cut-off for hyperfiltration (adjusted GFR > 90
th
 
percentile) (see discussion in paper 1), thus transforming a continuous variable into a 
dichotomous variable.  Our results may have been influenced by the chosen cut-off level. 
However, these results remained essentially the same when we repeated the analyses with a 
stricter definition of hyperfiltration (adjusted GFR > 95
th
 percentile).  
Because the nephron number varies significantly among individuals, increased whole-kidney 
GFRs could represent increased nephron endowment as well as elevated mean single 
nephron GFR.  It seems unlikely that our finding of hyperfiltration in the setting of impaired 
fasting glucose is caused by a higher nephron number in these individuals. The opposite 
would be more likely, as low birth weight has been associated with reduced nephron 
endowment and with later development of prediabetes or the metabolic syndrome [110].  
To increase the probability of detecting single nephron hyperfiltration, we adjusted our 
definition of hyperfiltration for factors assumed to influence the number of nephrons (age, 
sex, and height).  In both genders, GFR decreases after the age of 30 to 40 years, mainly 
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because of a decrease in the number of functioning nephrons [111]. Some, but not all studies 
have found the number of nephrons to be lower in females than in males [6;112;113].  Lower 
birth weight is associated with decreased nephron numbers and is strongly associated with 
lower adult height [114]. Although we are not aware of any studies that have investigated the 
association between height and nephron number, it seems reasonable to adjust for height. 
Accordingly, a nonadjusted threshold for renal hyperfiltration would mask single-nephron 
hyperfiltration in persons who are older, and possibly in women and in persons with a short 
stature. 
Absolute GFR correlates positively with body weight and decreases after weight reduction 
[40;115]. However, the nephron number does not increase in individuals who gain weight, 
but nephron size and the single-nephron GFR do, according to animal experiments [48]. In 
humans, a similar elevation in the single-nephron GFR with weight gain would be masked by 
the current practice of indexing GFR according to body surface area (BSA). Thus, if the 
purpose is to estimate the association between body weight and hyperfiltration, GFR should 
be treated as an absolute value without adjusting for BSA, as others have recommended 
[56;116]. On the other hand, because body weight, age and sex may be associated with both 
glucose metabolism and GFR, these factors could confound the association between, e.g., 
hyperglycemia and hyperfiltration. For this reason, we have chosen to correct the definition 
of renal hyperfiltration not only for age, gender and height but also for body weight.  
ACE-i and ARB use influence GFR and may be associated with fasting glucose levels [117]. 
Therefore, we also adjusted for these variables in the definition of hyperfiltration. However, 
the logistic regression analysis without this adjustment showed results that were essentially 
similar to those in table 3, paper 1. 
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5.1.4 External validity 
The external validity of a study expresses the generalizability of its results to other 
populations. The participants in the Tromsø 6 study were mainly Caucasians, and the study’s 
results are not necessarily applicable to other ethnicities. The associations between CVD risk 
factors and eGFR or mGFR may be different in other ethnic groups. However, there is no 
reason to assume that the main results of papers 1 and 2 are not applicable to Africans or 
Asians. Impaired glucose metabolism has recently been associated with elevated mGFR in a 
small study of Africans and with elevated eGFR in Japanese subjects [59;118]. Furthermore, 
the risk of CKD in diabetes is high worldwide, which indicates that hyperglycemia has a 
similar detrimental effect on kidney function in all ethnicities. A protective effect of physical 
exercise on early kidney decline has been found in both African Americans and Caucasians 
[35].  
The participants in our study were 50 to 62 years old. Thus, our results cannot automatically 
be generalized to other age groups.  However, we did not find an interaction between age and 
any of the independent risk factors in this restricted age group. Still, the associations between 
fasting glucose or insulin levels and GFR could be different in younger versus older 
individuals. This difference was indicated in a report from the PREVEND study, which 
included participants ranging in age from 28 to 75 years. In this population, higher insulin 
levels were associated with a tendency toward increased Ccr in younger individuals but 
normal or reduced Ccr in older individuals [88]. Indeed, hyperfiltration is hypothesized to 
cause a steeper age-related decline in GFR. However, insulin levels were not associated with 
hyperfiltration assessed by eGFR in a study of young healthy men [85]. Our finding of a 
positive association between plasma glucose and GFR was also reported in experimental 
studies in young healthy people and in both young and old patients with diabetes [67;119]. 
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Furthermore, the association between impaired fasting glucose and hyperfiltration was 
recently found in a Japanese population aged between 20 and 89 years old [59].  
We are not aware of any other reports on the modifying effects of exercise on the association 
between glucose and GFR. However, a protective effect of exercise on the risk of CKD or 
GFR decline has been indicated in two population-based studies with a wider age range than 
RENIS-T6 and in a study of individuals older than those included in RENIS-T6 [23;24;37].  
In paper 3, we found that eGFR was dependent on non-GFR-related factors. Similar results 
have been found in studies with wider age ranges; thus, we believe that the main results of 
paper 3 can be generalized to other age groups. 
5.1.5 Confounding 
The term confounding refers to a situation in which a noncausal association between a given 
exposure and an outcome is observed as a result of the influence of a third variable. This 
confounding variable is 1) causally associated with the outcome, 2) noncausally or causally 
associated with the exposure and 3) is not an intermediate variable in the causal pathway 
between exposure and outcome [100].  
In the current study, several healthy characteristics may be linked to GFR in addition to 
fasting glucose or physical exercise. Indeed, HDL cholesterol, triglycerides and current 
smoking were associated with glycemic status (table 1, paper 1), exercise (table 3, paper 2) 
and GFR (paper 3). However, the main results in papers 1 and 2 remained essentially the 
same after adjusting for known and possible determinants of GFR, including age, sex, 
weight, height, smoking, blood pressure, BMI, HDL cholesterol, triglycerides, insulin, ACR 
and ACE-i or ARB use. In paper 2, we also adjusted for ambulatory BP and heart rate.  
Nevertheless, there is always the possibility of residual confounding. 
Albuminuria is a putative confounder in our study. However, the results in papers 1 and 2 
remained essentially the same after adjusting for ACR (not shown). In paper 3, we used 
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different models of adjustments in which the fully adjusted model included traditional 
cardiovascular risk factors but not albuminuria or fasting glucose (see table 4 for details). 
These variables may have modified the associations between CVD risk factors and eGFR or 
mGFR. However, even if this should be the case, it does not alter the conclusion that eGFR is 
influenced by non-GFR-dependent factors. 
5.1.6 Single-sample iohexol clearance. 
GFR has day-to-day variability caused by measurement error and intraindividual biological 
variability. This variability introduces “noise” that makes it more difficult to detect true 
between-individual variations. Several precautions were taken to reduce measurement errors 
in RENIS-T6.  The GFR measurements were performed in a fasting state at the same time of 
the day for all subjects. We also standardized the procedure and used trained personnel who 
followed a strict protocol.   
The intraindividual coefficient of variation (CV) of GFR measurements varies according to 
the GFR level and the measurement method [9].  The CV for repeated measurements of 
plasma iohexol clearance (multiple sample) in the same individual has been reported to be 
between 5 and 6 % in the near-normal range of GFR [120;121], which was lower than the 
CVs for cystatin C, creatinine clearance or eGFRcre [121]. The single-sample iohexol 
clearance method has a performance comparable to the multi-sample method for either 
iohexol or 
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Cr-EDTA, particularly at GFR levels above 60 ml/min/m
2
 [10;122].  
The most important source of error in the single-sample iohexol clearance compared with the 
multiple-samples method is the formula that estimates the distribution volume of iohexol. 
This estimate is calculated according to weight and gender and is not very accurate. 
However, the imprecision in the estimate can be reduced by finding the optimal time point 
for the iohexol sample [89].  Another potential source of error and bias for the iohexol 
measurement in our study was that we used the same Teflon catheter to inject iohexol and to 
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collect serum samples for measuring the iohexol concentration. A small fraction of the 
injected iohexol could become entrapped in the plastic wall of the catheter, thereby creating a 
measurement error in the iohexol analysis sample. To minimize the contamination of the 
catheter, we flushed the catheter with 30 ml isotonic saline. This procedure has been 
evaluated (in 14 adult patients with GFR> 40 ml/min) and found to produce GFR results 
equal to those obtained from using two separate Teflon catheters [122].  
Ideally, we should have repeated the iohexol clearance method in a subsample of the RENIS-
T6 and validated the iohexol measurement with another gold standard. However, the single-
sample iohexol clearance method has been validated in other studies [9]. Furthermore, a true 
validation procedure would have had to be performed in another hospital to avoid the same 
“in-hospital” bias in the alternative gold standard method. This would have been expensive 
and inconvenient for the participant, and it was not feasible in this study. The age- and sex-
specific mean GFR values in our study were comparable to previously published data, as 
summarized by Hallan et al. [123]. Thus, any bias in the GFR measurements was most likely 
small. 
The iohexol measurement was performed with the HPLC method, which has been shown to 
have better reproducibility than the X-ray fluorescence method used in some other studies 
[9].  The interassay CV (analytical precision) of the HPLC analysis was 3.0%.  
5.1.7 Assessment of insulin resistance 
In our study, insulin resistance was assessed with the HOMA-IR and not measured with the 
gold standard, the euglycemic clamp method.  The reproducibility of HOMA-IR estimates 
has been shown to be low, partially because of the pulsatility of insulin secretion [93]. 
However, the HOMA-IR correlates well with values obtained with the euglycemic clamp 
technique (R = 0.88, p < 0.0001) and remains the preferred method for use in large 
epidemiological studies [93;124]. Nevertheless, suboptimal precision and reproducibility in 
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the insulin measurement and HOMA-IR may have diluted our regression estimates towards 
null.  
5.1.8 Hemolysis 
In our study, 180 (11%) serum samples had some degree of hemolysis due to problems with 
the blood sampling technique. The proportion of samples with hemolysis is close to that 
reported in other studies [125;126]. Hemolysis in the blood sample significantly influenced 
the mean insulin levels but not the mean GFR or fasting glucose levels. There was no change 
in regression estimates after excluding individuals with hemolysis in the serum samples.  
 
5.2 Discussion of the main results 
5.2.1 Fasting glucose and renal hyperfiltration 
We found that fasting glucose and impaired fasting glucose (IFG) was associated with 
hyperfiltration in a nondiabetic middle-aged population, independent of possible confounders 
such as age, gender, BMI, blood pressure and plasma lipids.  Furthermore, we found a 
similar effect of HbA1c on GFR. This result indicates that the association between glucose 
and GFR is not related to acute hyperglycemia secondary to stress during GFR measurement 
but is rather an effect of chronically elevated glucose on GFR. To the best of our knowledge, 
no previous studies have found an independent association between IFG or prediabetes and 
GFR. However, in agreement with our results, a recent study of 99140 persons who 
underwent health checkups in Japan observed that IFG was associated with hyperfiltration 
assessed with eGFRcre [59]. In agreement with our nonlinear effect of fasting glucose, they 
found a higher odds ratio of hyperfiltration when IFG was defined as fasting glucose > 6.1 
mmol/l compared to >5.6 mmol/l.   
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The exact mechanism of hyperfiltration in hyperglycemia is unknown. Vasodilatation of the 
afferent arteriole has been found in several experimental studies of diabetes, but 
vasoconstriction of the efferent arteriole with subsequent increased glomerular pressure has 
also been reported [64;127]. Recent studies indicate a key role of increased sodium 
reabsorption through sodium-glucose cotransport in the proximal renal tubulus [128;129], 
which decreases the delivery of sodium to the distal tubulus and could thereby increase GFR 
through the tubuloglomerular feedback system [130].  Hyperfiltration during hyperglycemia 
could also be related to nitric oxide, oxidative stress, vascular inflammation and activation of 
the renin-angiotensin system [129].  
We found that IFG was present in 40% of middle-aged men and in 18% of middle-aged 
women, which is in agreement with other studies [131]. The effect of IFG on the risk of 
CKD has not been fully elucidated. Fox et al. found the IFG increases the risk of CKD but 
not after adjustment for cardiovascular risk factors [27]. However, in that study, CKD was 
defined solely as a creatinine-based estimated GFR < 59 ml/min/1.73 m
2
 for woman and < 64 
ml/min/1.73 m
2
 for men. In two other studies, elevated fasting glucose or HbA1c predicted 
increased urinary albumin excretion in the general population when individuals with diabetes 
were excluded [25;26]. Higher levels of plasma glucose was also found to predict decline in 
GFR estimated by creatinine on three separate occasions during 6 years in a study of the 
general population [132].  
In our study, having IFG was not associated with increased urinary albumin excretion (table 
1, paper 1). It is possible that the relatively healthy participants in the present study were 
examined in an early phase of renal dysfunction, before an increase in albumin excretion has 
occurred, and that hyperfiltration still is a link between IFG and albuminuria. Potentially, 
hyperfiltration could also predispose to renal function decline without causing albuminuria, 
as recently found in a study of type II diabetes patients [72].  
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Finally, it is possible that hyperfiltration during hyperglycemia, but with the absence of other 
renal risk factors, may not be a major risk factor for albuminuria or decreased GFR. This 
suggestion is in accordance with the so-called multi-hit hypothesis of renal injury, where 
additional CKD risk factors are needed to cause kidney injury [133]. Low birth weight has 
been proposed as a congenital or “first hit” CKD risk factor because it is associated with 
reduced number of nephrons at birth. Congenital nephron deficit coexists with renal and 
glomerular hypertrophy, which indicate the presence of single nephron hyperfiltration 
already during the first months of life [110;134]. Low birth weight is also associated with 
impaired glucose tolerance and hypertension in adulthood, which add to the burden of renal 
risk [110]. Individuals with low birth weight have been found to have a 70% increased risk 
for developing CKD, defined as albuminuria, reduced GFR or end-stage renal disease [135]. 
The only prospective study of hyperfiltration in nondiabetics included subjects with Stage 1 
hypertension. In these subjects, hyperfiltration at baseline increased the hazard risk of 
albuminuria (HR 4.0 (CI, 2.1-9.2)) after 7.8 years [57].  
5.2.2 Insulin resistance and renal hyperfiltration 
Fasting insulin levels or insulin resistance assessed by HOMA-IR were not associated with 
hyperfiltration in our study when glucose was included in the regression models (table 2, 
paper 1).  Previous population-based studies of insulin and GFR are scarce, and none has 
measured GFR with an exact method. Two cross-sectional studies of the general population 
found a negative association between insulin levels and creatinine-based estimates of GFR 
[136;137]. In contrast to our study, these two studies included people with CKD.  The 
PREVEND study found that hyperinsulinemia was associated with a tendency towards 
hyperfiltration in young individuals but not in the elderly, even after adjustment for fasting 
glucose [88].  Our results indicated that plasma glucose, but not hyperinsulinemia or insulin 
resistance, was independently related to hyperfiltration in a middle-aged population. 
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Theoretically, insulin resistance may have been linked with a shorter period of hyperfiltration 
at a younger age, before the later reduction of GFR to normal levels or to reduced GFR at an 
older age.  
5.2.3 Smoking and renal hyperfiltration 
Current smoking was associated with mGFR (in linear regression; table 3, paper 3) and with 
the odds of hyperfiltration in the current study (see Section 4.4). Similar results have been 
found in previous studies in which renal function was assessed as eGFR. In these studies, 
confounding by lower muscle mass in smokers was suggested as a possible explanation. In 
our study, GFR was measured in a fasting state, including abstinence from tobacco. 
Accordingly, our findings may have been affected by a withdrawal phenomenon. Indeed, 
experimental studies have found reduced GFR immediately after smoking or the 
administration of nicotine [138;139]. However, in the PREVEND study, smoking was 
associated with hyperfiltration, as assessed by 24-hour urinary Ccr [87]. Moreover, a recent 
longitudinal study of 10118 middle-aged Japanese men found that current smokers had a 
1.32-times higher risk of developing glomerular hyperfiltration and a 1.51-times higher risk 
of proteinuria than nonsmokers during a 6-year follow-up period [140]. In light of these 
studies and our findings, there is now solid evidence of an association between smoking and 
hyperfiltration. 
5.2.4 Leisure-time exercise and renal hyperfiltration 
We found that leisure-time high-intensity exercise reduced the odds ratio for hyperfiltration 
in men. In women, a non-significant trend of reduced risk of hyperfiltration was found for 
exercise frequency. The association between exercise and renal hyperfiltration has not been 
investigated before. Some studies reported the cross-sectional association between physical 
activity and eGFR, with divergent results [141] [142]. In the third National Health and 
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Nutrition Examination Survey (NHANES III), frequency of physical activity was associated 
with a lower eGFRcre, while the activity calculated as metabolic equivalents was associated 
with an increased eGFRcre [141]. In that study, GFR was estimated using the Cockcroft-
Gault equation and was not adjusted to body surface area. Differences in body size of 
physically active versus inactive participants may therefore have confounded the results. 
Increased muscle mass in physically active subjects may also bias the results in studies of 
eGFRcre and exercise. In the Cardiovascular Health Study, a higher baseline eGFRcys, but 
not a higher eGFRcre, was found in physically active versus inactive older adults [37].  In 
this study, high-intensity exercise, but not moderate- or low-intensity exercise, reduced the 
hazard ratio for rapid kidney function decline (eGFRcys) during 7 years of follow-up.  In an 
Australian study of the general population, where they did not differentiate between high and 
low-intensive exercise, physical activity was not associated with the incidence of CKD based 
on eGFRcre or albuminuria. Our findings of reduced odds of hyperfiltration by high-intensity 
exercise offers a possible explanation for why exercise, particularly intensive exercise, is 
found to be a protective risk factor for urinary albumin excretion, renal function decline or 
CKD in some epidemiological studies [23;24;26;37] 
We do not have a good explanation for the gender disparity found in our study. Men 
and women may have interpreted the exercise questions in the questionnaire differently. On 
the other hand, gender-specific risk factors for early renal dysfunction have been observed 
previously. In the PREVEND study, Verhave et al. found a stronger association between 
cardiovascular risk factors and urinary albumin excretion in men than in women [143]. 
Similarly, results from the fourth Tromsø study showed that initiating strenuous physical 
activity ≥ 1 hour per week reduced the risk of increased albumin excretion in men but not in 
women [26]. In another report from the Tromsø study, physical activity at baseline predicted 
an increase in eGFRcre for women, but not for men, after 7 years [36]. However, in a large 
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cross-sectional study from the HUNT Study, Hallan et al. did not observe any gender 
differences in the odds of CKD by exercise, although the confidence intervals did not 
exclude a gender interaction [23]. Longitudinal studies on exercise and the risk of CKD are 
needed and should include the exercise intensity level and a gender-specific analysis.  
5.2.5 Leisure-time exercise, fasting glucose and GFR 
In RENIS-T6, fasting glucose was one of the strongest predictors of mGFR and was the 
strongest predictor of hyperfiltration. However, performing high-intensity exercise 
eliminated the effect of fasting glucose on mGFR in both genders and attenuated the effect of 
glucose on hyperfiltration. This novel finding may be of clinical importance. In animals, 
hyperfiltration combined with hyperglycemia has been shown to induce podocyte stress, 
podocyte injury, and cell apoptosis [144]. In humans, both hyperfiltration and borderline 
hyperglycemia have been associated with the progression of urinary albumin excretion and 
renal function decline [25;55;57;72;132]. However, there are no longitudinal studies on the 
effect of exercise on renal injury caused by hyperglycemia.  
Several beneficial effects of exercise could influence renal hemodynamics and urinary 
albumin excretion levels. Physical exercise, particularly high-intensity exercise, has been 
shown to improve endothelial function, decrease inflammation and oxidative stress, and 
reduce the activation of the renin-angiotensin-aldosterone system and renal sympathetic 
activity [79;81;82]. In a randomized study of 82 type II diabetes patients with metabolic 
syndrome, high-intensity exercise, but not low-intensity exercise, reduced urinary albumin 
excretion levels without any reduction in BMI or blood pressure [80]. In that study, HbA1c, 
HOMA-IR and inflammatory biomarkers were also reduced, which may have influenced 
urinary albumin excretion levels either through reduced hyperfiltration and/or some other 
mechanism, such as endothelial dysfunction. In the present study, metabolic factors such as 
insulin resistance (HOMA-IR), waist-to-hip ratio, heart rate and triglyceride levels did not 
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influence the effect of exercise on the association between glucose and mGFR. We did not 
measure markers of inflammation or oxidative stress. Emerging evidence links inflammation 
and oxidative stress to kidney injury and particularly to diabetic nephropathy [38]. 
Inflammation and oxidative stress increases in hyperglycemia and is reduced by exercise 
[38;79]. Several experimental studies also suggest that inflammation and oxidative stress 
induce hyperfiltration [83;84].    
Not all studies report independent effects of prediabetes and exercise on the development of 
albuminuria or CKD [27;142]. Our findings indicate that the renal risk of hyperglycemia may 
differ according to the level of physical exercise. Longitudinal studies should investigate the 
potential interaction between these variables. 
5.2.6 GFR estimated with cystatin C- and creatinine-based formulae  
In epidemiological research, GFR is usually estimated based on serum levels of creatinine or 
cystatin C. Cystatin C has been proposed as a promising marker of GFRs in the normal or 
upper range in the general population and in diabetic patients [145]. In our study, eGFRcys 
was not a superior method for the identification of individuals with hyperfiltration compared 
with eGFRcre (see Section 4.1.1) This result is consistent with results from two recent 
publications, one from RENIS-T6 and one validation study of eGFR in 448 type 2 diabetes 
patients, in which eGFRcre was found to perform equal to or better than eGFRcys in the 
normal range [92] [146]. Our results indicate that both eGFRcre and eGFRcys have low 
sensitivity for detecting individuals with hyperfiltration. Accordingly, results from 
hyperfiltration studies that use eGFR should be interpreted with caution.   
5.2.7 Cardiovascular risk factors and estimated GFR  
In paper 3, we found that estimated GFR was associated with traditional cardiovascular risk 
factors, even after adjusting for mGFR. eGFRcys was associated with smoking, BMI, HDL-
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cholesterol and triglycerides in the fully adjusted model. There were also nonlinear 
relationships between eGFRcre and BMI and between triglycerides and eGFRcys after 
adjustment for mGFR. These findings indicate that eGFR, particularly eGFRcys, is 
influenced by cardiovascular risk factors other than true GFR. These findings are in line with 
the results from the following two previous studies. In the PREVEND study, Knight et al. 
found that male gender, current smoking, greater weight, greater height and higher C-
reactive protein (CRP) were associated with higher cystatin C levels (lower eGFRcys) after 
adjustment for creatinine clearance [14]. However, creatinine clearance has limited precision, 
and the study included people with CVD. Therefore, these findings are not directly 
comparable to our results. Furthermore, we included BMI rather than height and weight, 
while Knight et al. did not include serum lipids as continuous variables in their analysis.  
Stevens et al. found that cystatin C was associated with several factors, including gender, 
BMI, CRP and hemoglobin, after adjusting for iothalamate clearance [15]. Their study 
included people with CKD, and the authors did not perform multivariate analyses.  
In our study, eGFRcre and mGFR showed a similar pattern of increased cardiovascular risk 
scores (the Framingham score) across increasing GFR quintiles for women (table 5, paper 3). 
However, eGFRcys was associated with a marked gradient in the opposite direction, that is, a 
lower cardiovascular risk score at higher eGFRcys in both sexes. These findings indicate that 
correct adjustment for confounding by cardiovascular risk factors in survival analyses is 
more critical for eGFRcys than eGFRcre. Several studies have found that elevated eGFRcre, 
as an indicator of hyperfiltration, is associated with increased mortality, whereas elevated 
eGFRcys is not [147;148]. This phenomenon has been explained by a possible confounding 
from chronic disease with muscle wasting and low creatinine production. Our results indicate 
that both a false overestimation of eGFRcre and a true elevated GFR (e.g., caused by 
smoking) could partly explain the increased mortality associated with elevated eGFRcre. 
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Although the abovementioned longitudinal studies adjusted for smoking and cardiovascular 
risk factors, the adjustment may have been insufficient due to the gender-specific and non-
linear associations between these risk factors and eGFR and mGFR. 
Studies of eGFR and CVD risk as well as studies of eGFR or hyperfiltration assessed using 
eGFR and albuminuria as an outcome could be biased, particularly in cystatin C studies. 
Obesity, smoking and inflammation (CRP), which influence (increase) cystatin C levels 
independently of mGFR, have been found to predict albuminuria.  As a consequence, the 
risks of developing albuminuria in studies of hyperfiltration based on eGFRcys could be 
biased (towards null) if proper adjustment is not performed. The non-GFR related effects of 
eGFR also represent a potential source of misclassification in studies where eGFR is used to 
define hyperfiltration (yes/no) without adjusting for these factors. Consequently, a higher 
proportion of women, a lower proportion of obese patients and a lower proportion of 
smokers could be falsely classified as having hyperfiltration assessed by cystatin C.  
6. CONCLUSIONS AND PERSPECTIVES 
We conclude that higher fasting glucose levels, but not higher fasting insulin levels, are 
associated with hyperfiltration in a general middle-aged population without diabetes. 
Furthermore, leisure-time high-intensity exercise reduced the odds ratio of hyperfiltration in 
men and eliminated the positive association between glucose and GFR in both sexes. The 
sensitivity and specificity of eGFRcre and eGFRcys for defining hyperfiltration is poor. 
eGFRcre and especially eGFRcys are influenced by non-GFR-related cardiovascular risk 
factors that may induce bias in longitudinal studies. The significance of hyperfiltration as a 
risk factor for CKD at the population level remains unknown. Longitudinal, population-
based studies of hyperfiltration assessed by measured GFR are needed.   
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PAPERS I-III 
 
APPENDIXES 
1 Hvordan vurderer du din egen helse sånn i  
alminnelighet?
c Meget god
c God
c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 
med andre på din alder?
c Mye bedre
c Litt bedre
c Omtrent lik
c Litt dårligere
c Mye dårligere
3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe)........................ c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer)............................... c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose)................................... c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som.du.har.søkt.hjelp.for)....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  
(til og med i dag)? (Sett ett kryss for hver plage)
Ikke
plaget
Litt 
plaget
Ganske 
mye
Veldig 
mye
Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis Ja; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom.fastlege/allmennlege/psykiater)........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat,.akupunktør,.fotsoneterapeut,.natur-
medisiner,.håndspålegger,.healer,.synsk.el.l)...... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 Konfidensielt
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .......................c c
Ved annen sykehuspoliklinikk .............c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 
medisiner? (Sett ett kryss for hver linje)
Aldri 
brukt Nå Før
Alder 
første 
gang
Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose)............................................. c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 
følgende medisiner? (Sett ett kryss pr linje) 
Ikke brukt 
siste 4 
uker
Sjeldnere 
enn hver 
uke
Hver  
uke, men 
ikke daglig Daglig
Smertestillende 
på resept ............... c c c c
Smertestillende 
uten resept .......... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe)....... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose).................. c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Diabetes før fylte 30 år ................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks..skrivebordsarbeid,.montering)
c Arbeid som krever at du går mye
(f.eks.ekspeditørarbeid,.lett.industriarbeid,.undervisning)
c Arbeid der du går og løfter mye
(f.eks.postbud,.pleier,.bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her.skal.du.også.regne.med.gang.
eller.sykling.til.arbeidsstedet,.søndagsturer.med.mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l..(merk.at.aktiviteten.skal.vare.minst.4.timer.i.uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon
c Sykepenger (er sykemeldt)
c Rehabiliterings-/attføringspenger
c Uføreytelse/pensjon, hel
c Uføreytelse/pensjon, delvis
c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)
Barn Fødselsår Fødselsvekt i gram
Ammet  
ant.mnd
1
2
3
4
5
6
39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  
(Sett ett kryss pr. linje)
Sjelden/
aldri
1-6
glass 
pr. uke
1 glass 
pr. dag
2-3  
glass  
pr. dag
4 glass 
el. mer 
pr. dag
Melk, kefir, 
yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året
c 7-12 g i året c Oftere
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45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Vitamin og eller mineraltilskudd ........... c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 
(sett 0 for de typene du ikke drikker daglig)
Antall kopper
Filterkaffe ...............................................................................
Kokekaffe/presskanne ...............................................
Annen kaffe .........................................................................
Te ...................................................................................................
56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 er du gravid nå?
c Ja c Nei c Usikker
Ved fRAMMøte vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)
0-1 g  
pr. mnd
2-3 g
pr.mnd
1-3 g
pr.uke
4-6 g
pr.uke
1-2 g
pr. dag
Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt .............................................. c c c c c
Kvernet kjøtt  
(pølser,.hamburger.o.l) ........... c c c c c
Mager fisk ............................... c c c c c
Fiskepålegg ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks,.ørret,.makrell,.sild,.kveite,uer)
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